Condition

Resectable Non-small Cell Lung Cancer

ClinicalTrials.gov condition label

Clinical trials9
Recruiting1
Common interventions20
Lead sponsors shown9

Clinical trials

9 shown
An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in GermanyNCT06169956 · 2023-11-30
RECRUITING
The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung CancerNCT07704645 · 2026-08-01
NOT_YET_RECRUITING
NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLCNCT07318636 · 2026-01-20
NOT_YET_RECRUITING
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLCNCT07038460 · 2025-07-01
NOT_YET_RECRUITING
Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical StudyNCT06946836 · 2025-04-21
NOT_YET_RECRUITING
A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLCNCT06485557 · 2024-08-01
UNKNOWN
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryNCT06161441 · 2024-07-16
ACTIVE_NOT_RECRUITING
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLCNCT05247684 · 2022-02-20
ACTIVE_NOT_RECRUITING
Mechanism of Action Trial of ColoAd1NCT02053220 · 2013-06-01
COMPLETED

Common interventions

CarboplatinDRUG2CisplatinDRUG2PaclitaxelDRUG2Adebrelimab Injection combined with HRS-7058 CapsuleDRUG1Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 InjectionDRUG1AK104DRUG1AK112DRUG1CemiplimabDRUG1Colo-Ad1BIOLOGICAL1FianlimabDRUG1Limertinib+chemotherapyDRUG1Limertinib+sintilimab+chemotherapyDRUG1Neoadjuvant nivolumab in combination with platinum-based chemotherapyDRUG1NK010BIOLOGICAL1OsimertinibDRUG1PD-1 antibodyDRUG1PemetrexedDRUG1PlaceboDRUG1sintilimab plus platinum-based chemotherapyDRUG1surgeryPROCEDURE1

Trial status mix

NOT_YET_RECRUITING4
ACTIVE_NOT_RECRUITING2
COMPLETED1
RECRUITING1
UNKNOWN1

Phase mix

PHASE25
PHASE12
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.